Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care
Conditions: Tuberculosis; Pre-XDR-TB; Extensively Drug-Resistant Tuberculosis; Multi Drug Resistant Tuberculosis; Rifampicin Resistant Tuberculosis Interventions: Drug: Bedaquiline Oral Tablet; Drug: Linezolid Oral Tablet; Drug: Delamanid in Oral Dosage Form; Drug: Clofazimine Oral Product; Drug: Levofloxacin Oral Tablet; Drug: Isoniazid Oral Product; Drug: Ethambutol Oral Product; Drug: Pyrazinamide Oral Pro duct Sponsors: Wits Health Consortium (Pty) Ltd; Regents of the University of California; University of Cape Town; Perina...
Source: ClinicalTrials.gov - August 20, 2019 Category: Research Source Type: clinical trials
Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care
Conditions: Tuberculosis; Pre-XDR-TB; Extensively Drug-Resistant Tuberculosis; Multi Drug Resistant Tuberculosis; Rifampicin Resistant Tuberculosis Interventions: Drug: Bedaquiline Oral Tablet; Drug: Linezolid Oral Tablet; Drug: Delamanid in Oral Dosage Form; Drug: Clofazimine Oral Product; Drug: Levofloxacin Oral Tablet; Drug: Isoniazid Oral Product; Drug: Ethambutol Oral Product; Drug: Pyrazinamide Oral Pro duct Sponsors: Wits Health Consortium (Pty) Ltd; Regents of the University of California; University of Cape Town; Perina...
Source: ClinicalTrials.gov - August 20, 2019 Category: Research Source Type: clinical trials
Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care
Conditions: Tuberculosis; Pre-XDR-TB; Extensively Drug-Resistant Tuberculosis; Multi Drug Resistant Tuberculosis; Rifampicin Resistant Tuberculosis Interventions: Drug: Bedaquiline Oral Tablet; Drug: Linezolid Oral Tablet; Drug: Delamanid in Oral Dosage Form; Drug: Clofazimine Oral Product; Drug: Levofloxacin Oral Tablet; Drug: Isoniazid Oral Product; Drug: Ethambutol Oral Product; Drug: Pyrazinamide Oral Pro duct Sponsors: Wits Health Consortium (Pty) Ltd; Regents of the University of California; University of Cape Town; Perina...
Source: ClinicalTrials.gov - August 20, 2019 Category: Research Source Type: clinical trials
FDA Advisory Committee Votes Favorably on the Question of the Effectiveness and Safety of Pretomanid in Combination with Bedaquiline and Linezolid for Treatment of Highly Drug-Resistant Forms of Tuberculosis
NEW YORK (June 6, 2019)—TB Alliance announced today that the U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee voted (14 yes, 4 no, 0 abstain) that there is substantial evidence of the effectiveness and sufficient... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 6, 2019 Category: Pharmaceuticals Source Type: clinical trials
PanACEA Sutezolid Dose-finding and Combination Evaluation
Conditions: Pulmonary Tuberculosis; Other Specified Pulmonary Tuberculosis Interventions: Drug: Sutezolid; Drug: Bedaquiline, Delamanid, Moxifloxacin; Drug: Midazolam oral solution Sponsors: Michael Hoelscher; European and Developing Countries Clinical Trials Partnership (EDCTP); Sequella, Inc.; Radboud University; University of California, San Francisco; German Federal Ministry of Education and Research Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 22, 2019 Category: Research Source Type: clinical trials
